U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07467434) titled 'FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases' on March 08.
Brief Summary: SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative mor...